Amprenavir vs Darunavir

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV protease · full HIV pipeline

Amprenavir

Rights held by GlaxoSmithKline; US product discontinued

Approved in HIVsmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Darunavir · Prezista

Marketed by Johnson & Johnson

Approved in HIVsmall molecule
Partial signal

NCT00110877 · Phase 3 · completed

The study randomly assigned 604 participants to darunavir/ritonavir or an active lopinavir/ritonavir comparator, but it was open-label rather than blinded. Its primary endpoint was a surrogate virologic measure. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: June 2027 · NCT06337032 (registry estimate)

Reported efficacy

Number of Participants with Viral load <400 copies/mL per TLOVR algorithm at Week 48 (Per Protocol Population) (48 weeks): HIV RNA <400 copies/mL at Week 48 (per-protocol population): darunavir-ritonavir 77% (220/286) vs lopinavir-ritonavir 68% (199/293); estimated difference 9% (95% CI 2-16). (met)

Result source: NCT00110877

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAmprenavirDarunavir
HIV-1 RNA below 50 copies/mL (week 48)—Not posted · NCT00002195—Not posted · NCT00110877
HIV-1 RNA 50 copies/mL or more (week 48)—Not posted · NCT00002195—Not posted · NCT00110877
CD4 count, change (week 48)—Not posted · NCT000021955 vs 41vs SBRwk 48 · n 85NCT01968551
1 other result
  • 23 vs 12 wk 24 · n 88 · Phase 3 · secondary NCT01968551

HIV-1 RNA below 50 copies/mL (week 48)

Amprenavir
—Not posted · NCT00002195
Darunavir
—Not posted · NCT00110877

HIV-1 RNA 50 copies/mL or more (week 48)

Amprenavir
—Not posted · NCT00002195
Darunavir
—Not posted · NCT00110877

CD4 count, change (week 48)

Amprenavir
—Not posted · NCT00002195
Darunavir
5 vs 41vs SBRwk 48 · n 85NCT01968551
1 other result
  • 23 vs 12 wk 24 · n 88 · Phase 3 · secondary NCT01968551
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Amprenavir: no structured comparison results are available for HIV.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Amprenavir: 0 of 4 rows · Darunavir: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDarunavir
Dropout rate
10%a
NCT01869634 · Phase 4 · registry result, not featured evidence
show 34 more results
—Darunavir/Ritonavir Alone
NCT00630734 · Phase 4 · registry result, not featured evidence · monotherapy
—Pravastatin + Darunavir/Ritonavir
NCT00630734 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00543101 · Phase 4 · registry result, not featured evidence
n/a: no completion milestoneContinued Treatment With DRV in Co
NCT01281813 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneContinued Treatment With DRV in Co
NCT01281813 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneContinued Treatment With DRV in Co
NCT01281813 · Phase 3 · registry result, not featured evidence · combination
—D/C/F/TAF: Extension Study
NCT03227861 · Phase 3 · registry result, not featured evidence
—D/C/F/TAF: Main Study
NCT03227861 · Phase 3 · registry result, not featured evidence
9.1%Cohort 1: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
3.3%Cohort 2: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
1.2%
NCT02155101 · Phase 3 · registry result, not featured evidence
22.2%Treatment-Experienced
NCT01440569 · Phase 3 · registry result, not featured evidence
12.2%Treatment-Naive
NCT01440569 · Phase 3 · registry result, not featured evidence
13.2%DRV/Rtv + 2NRTIs
NCT01448707 · Phase 3 · registry result, not featured evidence · combination
13.1%DRV/Rtv MONO
NCT01448707 · Phase 3 · registry result, not featured evidence
12.3%COBI+PI+2 NRTIs (Cohort 2)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
12.1%E/C/F/TDF (Cohort 1)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
11.3%
NCT01516970 · Phase 3 · registry result, not featured evidence
13.9%800/100 mg once daily
NCT00524368 · Phase 3 · registry result, not featured evidence
16.2%600/100 mg twice daily
NCT00524368 · Phase 3 · registry result, not featured evidence
18.9%800/100 mg once a day
NCT00458302 · Phase 3 · registry result, not featured evidence
12%
NCT00993148 · Phase 2 · registry result, not featured evidence · combination
0%800/100 mg
NCT01391013 · Phase 2 · registry result, not featured evidence · monotherapy
0%Combination Therapy
NCT01391013 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00915655 · Phase 2 · registry result, not featured evidence
4.8%
NCT00919854 · Phase 2 · registry result, not featured evidence
13.4%RAL + DRV/RTV
NCT00830804 · Phase 2 · registry result, not featured evidence · combination
—RAL+DRV/RTV
NCT00830804 · Phase 2 · registry result, not featured evidence · combination
0%Part A: SOF+EFV+ZDV/3TC (Cohort 2)
NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination
8.3%Part A: SOF+EFV/FTC/TDF (Cohort 1)
NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination
0%Part A: SOF+RAL+FTC/TDF (Cohort 5)
NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination
0%Part A: SOF+RTV+ATV+FTC/TDF (Cohor
NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination
0%Part A: SOF+RTV+DRV+FTC/TDF (Cohor
NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination
—Part B: SOF+PEG+RBV
NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination
Discontinued due to AEs
—a
NCT01869634 · Phase 4 · registry result, not featured evidence
show 34 more results
—Darunavir/Ritonavir Alone
NCT00630734 · Phase 4 · registry result, not featured evidence · monotherapy
—Pravastatin + Darunavir/Ritonavir
NCT00630734 · Phase 4 · registry result, not featured evidence · combination
—
NCT00543101 · Phase 4 · registry result, not featured evidence
0%Continued Treatment With DRV in Co
NCT01281813 · Phase 3 · registry result, not featured evidence · combination
7.3%Continued Treatment With DRV in Co
NCT01281813 · Phase 3 · registry result, not featured evidence · combination
0%Continued Treatment With DRV in Co
NCT01281813 · Phase 3 · registry result, not featured evidence · combination
—D/C/F/TAF: Extension Study
NCT03227861 · Phase 3 · registry result, not featured evidence
—D/C/F/TAF: Main Study
NCT03227861 · Phase 3 · registry result, not featured evidence
—Cohort 1: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
—Cohort 2: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
—
NCT02155101 · Phase 3 · registry result, not featured evidence
0%Treatment-Experienced
NCT01440569 · Phase 3 · registry result, not featured evidence
3%Treatment-Naive
NCT01440569 · Phase 3 · registry result, not featured evidence
0.7%DRV/Rtv + 2NRTIs
NCT01448707 · Phase 3 · registry result, not featured evidence · combination
2.2%DRV/Rtv MONO
NCT01448707 · Phase 3 · registry result, not featured evidence
4.1%COBI+PI+2 NRTIs (Cohort 2)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
6.1%E/C/F/TDF (Cohort 1)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
0.6%
NCT01516970 · Phase 3 · registry result, not featured evidence
3.4%800/100 mg once daily
NCT00524368 · Phase 3 · registry result, not featured evidence
4.1%600/100 mg twice daily
NCT00524368 · Phase 3 · registry result, not featured evidence
11%800/100 mg once a day
NCT00458302 · Phase 3 · registry result, not featured evidence
—
NCT00993148 · Phase 2 · registry result, not featured evidence · combination
—800/100 mg
NCT01391013 · Phase 2 · registry result, not featured evidence · monotherapy
—Combination Therapy
NCT01391013 · Phase 2 · registry result, not featured evidence · combination
—
NCT00915655 · Phase 2 · registry result, not featured evidence
4.8%
NCT00919854 · Phase 2 · registry result, not featured evidence
—RAL + DRV/RTV
NCT00830804 · Phase 2 · registry result, not featured evidence · combination
—RAL+DRV/RTV
NCT00830804 · Phase 2 · registry result, not featured evidence · combination
—Part A: SOF+EFV+ZDV/3TC (Cohort 2)
NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination
—Part A: SOF+EFV/FTC/TDF (Cohort 1)
NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination
—Part A: SOF+RAL+FTC/TDF (Cohort 5)
NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination
—Part A: SOF+RTV+ATV+FTC/TDF (Cohor
NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination
—Part A: SOF+RTV+DRV+FTC/TDF (Cohor
NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination
—Part B: SOF+PEG+RBV
NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination
Serious AEs
0%a
NCT01869634 · Phase 4 · registry result, not featured evidence
show 34 more results
0%Darunavir/Ritonavir Alone
NCT00630734 · Phase 4 · registry result, not featured evidence · monotherapy
3.6%Pravastatin + Darunavir/Ritonavir
NCT00630734 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00543101 · Phase 4 · registry result, not featured evidence
25%Continued Treatment With DRV in Co
NCT01281813 · Phase 3 · registry result, not featured evidence · combination
19%Continued Treatment With DRV in Co
NCT01281813 · Phase 3 · registry result, not featured evidence · combination
0%Continued Treatment With DRV in Co
NCT01281813 · Phase 3 · registry result, not featured evidence · combination
5%D/C/F/TAF: Extension Study
NCT03227861 · Phase 3 · registry result, not featured evidence
9.2%D/C/F/TAF: Main Study
NCT03227861 · Phase 3 · registry result, not featured evidence
4.8%Cohort 1: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
10.1%Cohort 2: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
3.7%
NCT02155101 · Phase 3 · registry result, not featured evidence
27.8%Treatment-Experienced
NCT01440569 · Phase 3 · registry result, not featured evidence
15.3%Treatment-Naive
NCT01440569 · Phase 3 · registry result, not featured evidence
10.3%DRV/Rtv + 2NRTIs
NCT01448707 · Phase 3 · registry result, not featured evidence · combination
13.1%DRV/Rtv MONO
NCT01448707 · Phase 3 · registry result, not featured evidence
15.1%COBI+PI+2 NRTIs (Cohort 2)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
18.2%E/C/F/TDF (Cohort 1)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
0.6%
NCT01516970 · Phase 3 · registry result, not featured evidence
5.4%800/100 mg once daily
NCT00524368 · Phase 3 · registry result, not featured evidence
9.1%600/100 mg twice daily
NCT00524368 · Phase 3 · registry result, not featured evidence
11%800/100 mg once a day
NCT00458302 · Phase 3 · registry result, not featured evidence
0%
NCT00993148 · Phase 2 · registry result, not featured evidence · combination
0%800/100 mg
NCT01391013 · Phase 2 · registry result, not featured evidence · monotherapy
0%Combination Therapy
NCT01391013 · Phase 2 · registry result, not featured evidence · combination
25%
NCT00915655 · Phase 2 · registry result, not featured evidence
9.5%
NCT00919854 · Phase 2 · registry result, not featured evidence
—RAL + DRV/RTV
NCT00830804 · Phase 2 · registry result, not featured evidence · combination
11.6%RAL+DRV/RTV
NCT00830804 · Phase 2 · registry result, not featured evidence · combination
0%Part A: SOF+EFV+ZDV/3TC (Cohort 2)
NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination
0%Part A: SOF+EFV/FTC/TDF (Cohort 1)
NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination
0%Part A: SOF+RAL+FTC/TDF (Cohort 5)
NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination
0%Part A: SOF+RTV+ATV+FTC/TDF (Cohor
NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination
0%Part A: SOF+RTV+DRV+FTC/TDF (Cohor
NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination
0%Part B: SOF+PEG+RBV
NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination
Most frequent reported AEs
a
nausea/vomiting/dyspepsia/abdominal pain 38.7%
diarrhea 25.8%
headache 25.8%
NCT00630734 · Phase 4 · registry result, not featured evidence · monotherapy
show 31 more results
diarrhea 46.4%
headache 21.4%
muscle pain 10.7%
NCT00630734 · Phase 4 · registry result, not featured evidence · combination
abnormal liver function test 33.3%
nasal congestion 25%
bronchitis 16.7%
NCT00543101 · Phase 4 · registry result, not featured evidence
pregnancy 0%
NCT01281813 · Phase 3 · registry result, not featured evidence · combination
pregnancy 2.9%
NCT01281813 · Phase 3 · registry result, not featured evidence · combination
pregnancy 0%
NCT01281813 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 6.3%
vitamin d deficiency 6.3%
pain in extremity 5%
NCT03227861 · Phase 3 · registry result, not featured evidence
diarrhoea 24.8%
nausea 15.6%
headache 9.2%
NCT03227861 · Phase 3 · registry result, not featured evidence
acute sinusitis 19%
bronchitis 14.3%
sinusitis 14.3%
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
back pain 12.4%
upper respiratory tract infection 11.2%
bronchitis 6.7%
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
acute hepatitis b 1.2%
hypertension 1.2%
pulmonary tb 1.2%
NCT02155101 · Phase 3 · registry result, not featured evidence
diarrhoea 44.4%
nasopharyngitis 22.2%
sinusitis 22.2%
NCT01440569 · Phase 3 · registry result, not featured evidence
diarrhoea 33.6%
nausea 27.1%
upper respiratory tract infection 23.7%
NCT01440569 · Phase 3 · registry result, not featured evidence
nasopharyngitis 8.1%
diarrhoea 7.4%
headache 6.6%
NCT01448707 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 13.1%
nasopharyngitis 11.7%
back pain 7.3%
NCT01448707 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 20.5%
nasopharyngitis 19.2%
bronchitis 13.7%
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 36.4%
insomnia 21.2%
headache 18.2%
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 28.3%
nausea 15.1%
fatigue 13.2%
NCT01516970 · Phase 3 · registry result, not featured evidence
800/100 mg once daily
diarrhoea 14.3%
nausea 12.9%
headache 6.8%
NCT00524368 · Phase 3 · registry result, not featured evidence
600/100 mg twice daily
diarrhoea 22.3%
nausea 14.2%
vomiting 8.4%
NCT00524368 · Phase 3 · registry result, not featured evidence
800/100 mg once a day
diarrhoea 20.5%
hypercholesterolaemia 15%
nasopharyngitis 11.8%
NCT00458302 · Phase 3 · registry result, not featured evidence
800/100 mg
blood cholesterol increased 26.7%
low density lipoprotein increased 26.7%
pyrexia 20%
NCT01391013 · Phase 2 · registry result, not featured evidence · monotherapy
diarrhoea 20%
blood creatine phosphokinase increased 13.3%
blood triglycerides increased 6.7%
NCT01391013 · Phase 2 · registry result, not featured evidence · combination
anaemia 25%
nausea 25%
vomiting 25%
NCT00915655 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 28.6%
cough 23.8%
diarrhoea 23.8%
NCT00919854 · Phase 2 · registry result, not featured evidence
blood cholesterol 40.2%
low density lipoprotein abnormal 30.4%
aspartate aminotransferase increased 13.4%
NCT00830804 · Phase 2 · registry result, not featured evidence · combination
abdominal pain 0%
agitation 0%
anaemia 0%
NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination
agitation 8.3%
body temperature decreased 8.3%
chills 8.3%
NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination
dry mouth 14.3%
haemorrhoids 14.3%
abdominal pain 0%
NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination
abdominal pain 0%
agitation 0%
anaemia 0%
NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination
cough 14.3%
fungal skin infection 14.3%
nasal congestion 14.3%
NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination
anaemia 52.2%
fatigue 34.8%
hyperbilirubinaemia 17.4%
NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Darunavir

Lamina Propria CD4 T Cell Density 213 cells/uL @ 52wk
absolute change · cells/uL
No placebo or comparator arm
12-months after ART
NCT01869634 · Phase 4 · registry result, not featured evidence
Virologic Suppression 100% (n=12) vs 100% (n=12) Current Dual Boosted PI @ 24wk
responder rate · % of participants
NCT00543101 · Phase 4 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies 84.4% (n=109) @ 48wk
responder rate · % of participants
No placebo or comparator arm
NCT03227861 · Phase 3 · registry result, not featured evidence
show 11 more results
81.7% (n=109) @ 24wk
NCT03227861 · Phase 3 · registry result, not featured evidence
83.7% (n=295) @ 24wk
NCT01440569 · Phase 3 · registry result, not featured evidence
61.1% (n=18) @ 24wk
NCT01440569 · Phase 3 · registry result, not featured evidence
82.7% (n=295) @ 48wk
NCT01440569 · Phase 3 · registry result, not featured evidence
50% (n=18) @ 48wk
NCT01440569 · Phase 3 · registry result, not featured evidence
78.8% (n=33) @ 48wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
88.9% (n=33) @ 96wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
82.2% (n=73) @ 48wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
90.7% (n=73) @ 96wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
84.8% (n=33) @ 24wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
90.4% (n=73) @ 24wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
HIV-1 RNA -1.65 log @ 2wk
absolute change · log
No placebo or comparator arm
NCT03227861 · Phase 3 · registry result, not featured evidence
show 9 more results
-2.02 log @ 4wk
NCT03227861 · Phase 3 · registry result, not featured evidence
-2.43 log @ 8wk
NCT03227861 · Phase 3 · registry result, not featured evidence
-2.78 log @ 12wk
NCT03227861 · Phase 3 · registry result, not featured evidence
-3.08 log @ 24wk
NCT03227861 · Phase 3 · registry result, not featured evidence
-3.14 log @ 36wk
NCT03227861 · Phase 3 · registry result, not featured evidence
-3.14 log @ 48wk
NCT03227861 · Phase 3 · registry result, not featured evidence
-2.04 log @ 24wk
NCT00919854 · Phase 2 · registry result, not featured evidence
-2.14 log @ 48wk
NCT00919854 · Phase 2 · registry result, not featured evidence
-1.67 log @ 1wk
NCT00830804 · Phase 2 · registry result, not featured evidence · combination
CD4+ 149.56 cells/uL @ 12wk
absolute change · cells/uL
No placebo or comparator arm
NCT03227861 · Phase 3 · registry result, not featured evidence
show 8 more results
182.11 cells/uL @ 24wk
NCT03227861 · Phase 3 · registry result, not featured evidence
222.6 cells/uL @ 48wk
NCT03227861 · Phase 3 · registry result, not featured evidence
145 cells/uL @ 24wk
NCT01440569 · Phase 3 · registry result, not featured evidence
99 cells/uL @ 24wk
NCT01440569 · Phase 3 · registry result, not featured evidence
194 cells/uL @ 48wk
NCT01440569 · Phase 3 · registry result, not featured evidence
121 cells/uL @ 48wk
NCT01440569 · Phase 3 · registry result, not featured evidence
247 cells/uL @ 96wk
NCT00993148 · Phase 2 · registry result, not featured evidence · combination
200 cells/uL @ 48wk
NCT00830804 · Phase 2 · registry result, not featured evidence · combination
Virologic Failure 0% (n=109) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT03227861 · Phase 3 · registry result, not featured evidence
show 3 more results
0% (n=109) @ 48wk
NCT03227861 · Phase 3 · registry result, not featured evidence
10.6% (n=80) @ 72wk
NCT03227861 · Phase 3 · registry result, not featured evidence
9.1% (n=80) @ 96wk
NCT03227861 · Phase 3 · registry result, not featured evidence
HIVTSQs Total 56.52 score @ 4wk
absolute value · score
No placebo or comparator arm
NCT03227861 · Phase 3 · registry result, not featured evidence
show 2 more results
57.87 score @ 24wk
NCT03227861 · Phase 3 · registry result, not featured evidence
57.88 score @ 48wk
NCT03227861 · Phase 3 · registry result, not featured evidence
HIV-1 RNA LT 50 Copies 96.6% (n=89) vs 91.3% (n=46) SBR @ 24wk
responder rate · % of participants
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
94.4% (n=89) vs 76.1% (n=46) SBR @ 48wk
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
CD4+ 23 vs 12 SBR cells/uL @ 24wk
absolute change · cells/uL
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
5 vs 41 SBR cells/uL @ 48wk
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
Virologic Suppression 88.9% (n=81) vs 94.9% (n=39) ART With 2 NRTIs Plus LPV/r (or ATV/r) @ 24wk
event count · % of participants
NCT02155101 · Phase 3 · registry result, not featured evidence · converted to % from 72 Participants as posted
show 2 more results
90.1% (n=81) vs 89.7% (n=39) ART With 2 NRTIs Plus LPV/r (or ATV/r) @ 12wk*
NCT02155101 · Phase 3 · registry result, not featured evidence · converted to % from 73 Participants as posted
76.5% (n=81) vs 92.3% (n=39) ART With 2 NRTIs Plus LPV/r (or ATV/r) @ 24wk*
NCT02155101 · Phase 3 · registry result, not featured evidence · converted to % from 62 Participants as posted
Virologic 87% (n=137) @ 48wk
responder rate · % of participants
No placebo or comparator arm
NCT01448707 · Phase 3 · registry result, not featured evidence
show 7 more results
95% (n=136) @ 48wk
NCT01448707 · Phase 3 · registry result, not featured evidence · combination
75.2% (n=137) @ 96wk
NCT01448707 · Phase 3 · registry result, not featured evidence
85.3% (n=136) @ 96wk
NCT01448707 · Phase 3 · registry result, not featured evidence · combination
93% (n=137) @ 48wk
NCT01448707 · Phase 3 · registry result, not featured evidence
96.5% (n=136) @ 48wk
NCT01448707 · Phase 3 · registry result, not featured evidence · combination
89.3% (n=137) @ 96wk
NCT01448707 · Phase 3 · registry result, not featured evidence
89.9% (n=136) @ 96wk
NCT01448707 · Phase 3 · registry result, not featured evidence · combination
Neurocognitive Composite 0.39 score @ 48wk
absolute change · score
No placebo or comparator arm
NCT01448707 · Phase 3 · registry result, not featured evidence
show 3 more results
0.42 score @ 48wk
NCT01448707 · Phase 3 · registry result, not featured evidence · combination
0.63 score @ 96wk
NCT01448707 · Phase 3 · registry result, not featured evidence
0.57 score @ 96wk
NCT01448707 · Phase 3 · registry result, not featured evidence · combination

+ 37 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Amprenavir's landscape · Darunavir's landscape